Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Jul 12, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mineralys Therapeutics, Inc.
| -10.76K |
$13.14 | -$141,394.31 | -4.16% | 247.61K |
Jul 11
|
Scheduled
| ||||||
Mineralys Therapeutics, Inc.
| -96.81K |
$12.94 | -$1,252,718.33 | -27.48% | 255.46K |
Jun 11
|
Scheduled
| ||||||
Mineralys Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 13
| |||||||
Mineralys Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Mar 17
| |||||||
Mineralys Therapeutics, Inc.
| 6.25K |
$16.00 | $100,000.00 | +1.81% | 350.81K | +1 |
Feb 14
| ||||||
Mineralys Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Feb 9
| ||||||
Mineralys Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 | |||||||
Brickell Biotech, Inc.
|
0
|
—
|
—
|
—
|
0
|
Mar 16
| |||||||
Brickell Biotech, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Miragen Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 6
| |||||||
Miragen Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Miragen Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Miragen Therapeutics, Inc.
| 9.09K |
$5.50 | $49,995.00 | +626.90% | 10.54K |
Feb 13
| |||||||
Miragen Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jan 31
| |||||||
Miragen Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Miragen Therapeutics, Inc.
| 200 |
$7.55 | $1,510.00 |
∞
| 200 |
Jun 22
| |||||||
Miragen Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Feb 16
| |||||||
Viridian Therapeutics, Inc.\de
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||